..
With new trial data, it has become quite unlikely that ivermectin has a meaningful benefit in the treatment of COVID-19
— Health Nerd (@GidMK) June 14, 2022
My new piece https://t.co/joX0HIJOYR
..
— KittyPooh (@KittyPo80176717) June 14, 2022
https://www.medrxiv.org/content/10.1101/2022.06.10.22276252v1
..
Another large, robust randomized trial has failed to find a meaningful benefit for ivermectin for COVID-19 https://t.co/F3ZekR1LYn
— Health Nerd (@GidMK) June 13, 2022
This is what I'd call a fairly convincingly null trial. Ivm did:
— Health Nerd (@GidMK) June 13, 2022
– worse on deaths/hospitalizations
– better on time to recovery
– better on symptom severity
– worse on ED visits
than placebo, none of them statistically significant
Will be writing this up into a piece tomorrow, but with such a tiny/no benefit on yet another large trial it is now becoming very unlikely that there will be any utility for ivermectin as a treatment for COVID-19 (jury still out on prevention)
— Health Nerd (@GidMK) June 13, 2022
..
NIH ACTIV-6 #ivermectin early #covid19 treatment results with 1591 randomized participants.
— David Boulware, MD MPH (@boulware_dr) June 13, 2022
No difference in ER visits, hospitalizations, deaths (all numerically higher with IVM, but no statistical difference).
Time to recovery 11 vs 11.5 days. #idtwitterhttps://t.co/c5ZdMQwfyI
The symptom duration data are interesting. The trial is large enough that it can detect differences that are not clinically meaningful, but there are some subgroups that are interesting. Not conclusive as they are small, but hypothesis generating for verification in future arm
— David Boulware, MD MPH (@boulware_dr) June 13, 2022
Thus, if the debate is over whether there is zero difference or a small, clinically non-meaningful difference – let the debate start.
— David Boulware, MD MPH (@boulware_dr) June 13, 2022
Hazard Ratio observed = 1.07 (95%CI, 0.96, 1.17)
Here's what a theoritical Hazard Ratio of 0.66 or 1.50 would look like. That's a difference. pic.twitter.com/Aq844EIWI1
One write up by @carlzimmer in the @NYTimes on the ACTIV-6 trial with quote from the two co-PIs. https://t.co/3OKMPm32Sd
— David Boulware, MD MPH (@boulware_dr) June 13, 2022
Here is a link to the ACTIV-6 website which explains more about the trial and results. https://t.co/tW8BZn3guW
— David Boulware, MD MPH (@boulware_dr) June 13, 2022
More details on the trial and trial results can be found at: https://t.co/Om1IfjE7Pz pic.twitter.com/SQ8rQIPx2n
— David Boulware, MD MPH (@boulware_dr) June 13, 2022
..
weehingthong 